Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm‐associated venous thromboembolism in a large tertiary centre in the UK
Natalia Curto‐García(Guy's and St Thomas' NHS Foundation Trust), Claire Harrison(University of Namur), Beverley J. Hunt, Karen Breen(University College London Hospitals NHS Foundation Trust), Andrew J. Doyle(St Thomas' Hospital), Donal P. McLornan(University College Hospital), Gavin Ling(Guy's and St Thomas' NHS Foundation Trust), Deepti Radia(Guy's and St Thomas' NHS Foundation Trust)
Cited by 31
Related Papers
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
|British Journal of Haematology|2012|861
Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis
|European Journal of Vascular and Endovascular Surgery|2020|709